However, a clinical study that selected lung cancer patients of all histologies for treatment with the multikinase inhibitor ponatinib based on FGFR1 amplification and mRNA expression revealed a low rate of concordance between FGFR1 amplification and actual mRNA (thus protein) expression.40 In fact, the same study showed that of 126 patients with FGFR1 mRNA overexpression, only 6 concordantly had FGFR1 amplification. Here, FGFR1 is linked to lung cancer.